Identification of breast cancer patients with pathologic complete response in the breast after neoadjuvant systemic treatment by an intelligent vacuum-assisted biopsy.

Artificial intelligence Breast cancer Individualized treatment Machine learning Neoadjuvant systemic treatment Pathologic complete response Surgical oncology Vacuum-assisted biopsy

Journal

European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373

Informations de publication

Date de publication:
01 2021
Historique:
received: 06 09 2020
revised: 26 10 2020
accepted: 09 11 2020
pubmed: 12 12 2020
medline: 24 4 2021
entrez: 11 12 2020
Statut: ppublish

Résumé

Neoadjuvant systemic treatment elicits a pathologic complete response (pCR) in about 35% of women with breast cancer. In such cases, breast surgery may be considered overtreatment. We evaluated multivariate algorithms using patient, tumor, and vacuum-assisted biopsy (VAB) variables to identify patients with breast pCR. We developed and tested four multivariate algorithms: a logistic regression with elastic net penalty, an Extreme Gradient Boosting (XGBoost) tree, Support Vector Machines (SVM), and neural network. We used data from 457 women, randomly partitioned into training and test set (2:1), enrolled in three trials with stage 1-3 breast cancer, undergoing VAB before surgery. False-negative rate (FNR) and specificity were the main outcome measures. The best performing algorithm was validated in an independent fourth trial. In the test set (n = 152), the logistic regression with elastic net penalty, XGboost tree, SVM, and neural network revealed an FNR of 1.2% (1 of 85 patients with missed residual cancer). Specificity of the logistic regression with elastic net penalty was 52.2% (35 of 67 women with surgically confirmed breast pCR identified), of the XGBoost tree 55.2% (37 of 67), of SVM 62.7% (42 of 67), and of the neural network 67.2% (45 of 67). External validation (n = 50) of the neural network showed an FNR of 0% (0 of 27) and a specificity of 65.2% (15 of 23). Area under the ROC curve for the neural network was 0.97 (95% CI, 0.94-1.00). A multivariate algorithm can accurately select breast cancer patients without residual cancer after neoadjuvant treatment.

Sections du résumé

BACKGROUND
Neoadjuvant systemic treatment elicits a pathologic complete response (pCR) in about 35% of women with breast cancer. In such cases, breast surgery may be considered overtreatment. We evaluated multivariate algorithms using patient, tumor, and vacuum-assisted biopsy (VAB) variables to identify patients with breast pCR.
METHODS
We developed and tested four multivariate algorithms: a logistic regression with elastic net penalty, an Extreme Gradient Boosting (XGBoost) tree, Support Vector Machines (SVM), and neural network. We used data from 457 women, randomly partitioned into training and test set (2:1), enrolled in three trials with stage 1-3 breast cancer, undergoing VAB before surgery. False-negative rate (FNR) and specificity were the main outcome measures. The best performing algorithm was validated in an independent fourth trial.
RESULTS
In the test set (n = 152), the logistic regression with elastic net penalty, XGboost tree, SVM, and neural network revealed an FNR of 1.2% (1 of 85 patients with missed residual cancer). Specificity of the logistic regression with elastic net penalty was 52.2% (35 of 67 women with surgically confirmed breast pCR identified), of the XGBoost tree 55.2% (37 of 67), of SVM 62.7% (42 of 67), and of the neural network 67.2% (45 of 67). External validation (n = 50) of the neural network showed an FNR of 0% (0 of 27) and a specificity of 65.2% (15 of 23). Area under the ROC curve for the neural network was 0.97 (95% CI, 0.94-1.00).
CONCLUSION
A multivariate algorithm can accurately select breast cancer patients without residual cancer after neoadjuvant treatment.

Identifiants

pubmed: 33307491
pii: S0959-8049(20)31325-3
doi: 10.1016/j.ejca.2020.11.006
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT02455791', 'NCT02948764', 'NCT03273426', 'NCT02575612']

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

134-146

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

André Pfob (A)

Department of Gynecology, Heidelberg University, Heidelberg, Germany.

Chris Sidey-Gibbons (C)

Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, USA.

Han-Byoel Lee (HB)

Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea; Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea; Cancer Research Institute, Seoul National University, Seoul, South Korea.

Marios Konstantinos Tasoulis (MK)

Department of Breast Surgery, The Royal Marsden NHS Foundation Trust, London, United Kingdom.

Vivian Koelbel (V)

Department of Gynecology, Heidelberg University, Heidelberg, Germany.

Michael Golatta (M)

Department of Gynecology, Heidelberg University, Heidelberg, Germany.

Gaiane M Rauch (GM)

Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, USA.

Benjamin D Smith (BD)

Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, USA.

Vicente Valero (V)

Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.

Wonshik Han (W)

Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea; Biomedical Research Institute, Seoul National University Hospital, Seoul, South Korea; Cancer Research Institute, Seoul National University, Seoul, South Korea.

Fiona MacNeill (F)

Department of Breast Surgery, The Royal Marsden NHS Foundation Trust, London, United Kingdom.

Walter Paul Weber (WP)

Department of Breast Surgery, University Hospital Basel and University of Basel, Basel, Switzerland.

Geraldine Rauch (G)

Institute of Biometry and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, And Berlin Institute of Health, Berlin, Germany.

Henry M Kuerer (HM)

Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA.

Joerg Heil (J)

Department of Gynecology, Heidelberg University, Heidelberg, Germany. Electronic address: Joerg.Heil@med.uni-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH